Dr Marta Casarrubios speaks to ecancer in an online interview as part of the ELCC 2022 meeting about immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Dr Casarrubios explains about the methods they used and which gene signatures they looked at, before going into detail about their findings.

She concludes by talking about what can be taken away from these results and their potential for clinical impact.